secwatch.observer — SEC 8-K summary
======================================

Issuer:     PLIANT THERAPEUTICS, INC. (PLRX)
CIK:        0001746473
Form:       8-K
Filed at:   2026-03-11T23:59:59+00:00
Accession:  0001746473-26-000039
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pliant Therapeutics reports Q4 2025 net loss of $23.6M; advances PLN-101095 Phase 1b after positive ICI-refractory data
--------------------------------------------------------------------------------

- PLN-101095 Phase 1: 4 responders (1 CR, 3 PR) out of 10 secondary ICI-refractory patients; IFN-γ biomarker correlated with response.
- Accelerated development: Phase 1b indication expansion trial initiated for NSCLC, RCC, high TMB; first patient enrollment expected Q2 2026.
- Q4 2025 net loss $23.6M vs $49.7M YoY; R&D expense fell to $15.6M from $38.8M due to BEACON-IPF discontinuation.
- Cash, equivalents and short-term investments $192.4M; expected to fund operations into second half 2028.
- Appointed Minnie Kuo as COO; INTEGRIS-PSC Phase 2 results published in Journal of Hepatology (Jan 2026).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1746473/000174647326000039/0001746473-26-000039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1746473/000174647326000039/plrx-20260311.htm
  HTML page:      https://secwatch.observer/filing/0001746473-26-000039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer